141 related articles for article (PubMed ID: 23149915)
1. Bcl3 selectively promotes metastasis of ERBB2-driven mammary tumors.
Wakefield A; Soukupova J; Montagne A; Ranger J; French R; Muller WJ; Clarkson RW
Cancer Res; 2013 Jan; 73(2):745-55. PubMed ID: 23149915
[TBL] [Abstract][Full Text] [Related]
2. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
[TBL] [Abstract][Full Text] [Related]
3. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
Ursini-Siegel J; Rajput AB; Lu H; Sanguin-Gendreau V; Zuo D; Papavasiliou V; Lavoie C; Turpin J; Cianflone K; Huntsman DG; Muller WJ
Mol Cell Biol; 2007 Sep; 27(18):6361-71. PubMed ID: 17636013
[TBL] [Abstract][Full Text] [Related]
4. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten.
Barbieri I; Pensa S; Pannellini T; Quaglino E; Maritano D; Demaria M; Voster A; Turkson J; Cavallo F; Watson CJ; Provero P; Musiani P; Poli V
Cancer Res; 2010 Mar; 70(6):2558-67. PubMed ID: 20215508
[TBL] [Abstract][Full Text] [Related]
5. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice.
Sacco MG; Barbieri O; Piccini D; Noviello E; Zoppé M; Zucchi I; Frattini A; Villa A; Vezzoni P
Gene Ther; 1998 Mar; 5(3):388-93. PubMed ID: 9614559
[TBL] [Abstract][Full Text] [Related]
7. β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.
Schade B; Lesurf R; Sanguin-Gendreau V; Bui T; Deblois G; O'Toole SA; Millar EK; Zardawi SJ; Lopez-Knowles E; Sutherland RL; Giguère V; Kahn M; Hallett M; Muller WJ
Cancer Res; 2013 Jul; 73(14):4474-87. PubMed ID: 23720052
[TBL] [Abstract][Full Text] [Related]
8. B-cell CLL/lymphoma 3 promotes glioma cell proliferation and inhibits apoptosis through the oncogenic STAT3 pathway.
Wu J; Li L; Jiang G; Zhan H; Wang N
Int J Oncol; 2016 Dec; 49(6):2471-2479. PubMed ID: 27748795
[TBL] [Abstract][Full Text] [Related]
9. The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.
Turpin J; Ling C; Crosby EJ; Hartman ZC; Simond AM; Chodosh LA; Rennhack JP; Andrechek ER; Ozcelik J; Hallett M; Mills GB; Cardiff RD; Gray JW; Griffith OL; Muller WJ
Oncogene; 2016 Nov; 35(47):6053-6064. PubMed ID: 27157621
[TBL] [Abstract][Full Text] [Related]
10. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
11. In vivo evidence supporting a metastasis suppressor role for Stard13 (Dlc2) in ErbB2 (Neu) oncogene induced mouse mammary tumors.
Basak P; Leslie H; Dillon RL; Muller WJ; Raouf A; Mowat MRA
Genes Chromosomes Cancer; 2018 Apr; 57(4):182-191. PubMed ID: 29218825
[TBL] [Abstract][Full Text] [Related]
12. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
13. Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene.
Barbieri I; Quaglino E; Maritano D; Pannellini T; Riera L; Cavallo F; Forni G; Musiani P; Chiarle R; Poli V
Mol Carcinog; 2010 Feb; 49(2):114-20. PubMed ID: 20027636
[TBL] [Abstract][Full Text] [Related]
14. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.
Guy CT; Webster MA; Schaller M; Parsons TJ; Cardiff RD; Muller WJ
Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10578-82. PubMed ID: 1359541
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine phosphatase PTPα contributes to HER2-evoked breast tumor initiation and maintenance.
Meyer DS; Aceto N; Sausgruber N; Brinkhaus H; Müller U; Pallen CJ; Bentires-Alj M
Oncogene; 2014 Jan; 33(3):398-402. PubMed ID: 23318421
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the protein tyrosine phosphatase PRL-2 correlates with breast tumor formation and progression.
Hardy S; Wong NN; Muller WJ; Park M; Tremblay ML
Cancer Res; 2010 Nov; 70(21):8959-67. PubMed ID: 20841483
[TBL] [Abstract][Full Text] [Related]
17. Loss of the 14-3-3σ tumor suppressor is a critical event in ErbB2-mediated tumor progression.
Ling C; Su VM; Zuo D; Muller WJ
Cancer Discov; 2012 Jan; 2(1):68-81. PubMed ID: 22585169
[TBL] [Abstract][Full Text] [Related]
18. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
[TBL] [Abstract][Full Text] [Related]
19. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.
Jacquemart IC; Springs AE; Chen WY
Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488
[TBL] [Abstract][Full Text] [Related]
20. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E
Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
